Uterine Fibroids are the most common benign, non-cancerous tumors of a woman’s uterus, most often seen during the childbearing years.Fibroids are only treated if they cause symptoms and treatment options to range from medications to invasive surgery.
The market is primarily driven by increasing patient pool owing to increasing female geriatric population, growing prevalence of hormonal disorders and changing lifestyle. However, high R&D cost is likely to hinder market growth.
The Uterine Fibroids Treatment market report segments the market by type, by treatment type, and by region.
Based on the type of fibroid, the market comprises of:
• Subserosal Fibroids
• Intramural Fibroids
• Submucosal Fibroids
• Pedunculated
Based on treatment type, the market is categorized into:
• Hormone therapy
• Gonadotropin-releasing hormone agonists
• Uterine artery embolization
• Myomectomy
• Hysterectomy
Treatment options for traditional surgical procedures include abdominal myomectomy and hysterectomy. Other non-standard but new treatments available for uterine fibroids include Radiofrequency ablation and Anti-hormonal drugs.
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: